Risk Management and Healthcare Policy · Nov 14, 2026

Quantitative Evaluation of Semaglutide-Associated Changes in Gastric Antral Motility Using Oral Contrast-Enhanced Gastric Ultrasonography

By Xu LY, Han D, Zhu YM et al.

OBJECTIVE: To quantitatively evaluate changes in gastric antral motility before and after semaglutide administration using oral contrast-enhanced gastric ultrasonography, providing imaging-based quantitative evidence for assessing the gastrointestinal effects of semaglutide in clinical practice. METHODS: This prospective study enrolled 60 patients with obesity or diabetes mellitus who were randomly assigned to the semaglutide or control group. Gastric ultrasonography was performed at baseline, 4 weeks, and 8 weeks. Concurrently, a gastrointestinal transit test was conducted: patients ingested a barium marker capsule when 200 mL of contrast agent remained, with abdominal radiography performed at 2 and 4 hours post-ingestion. RESULTS: No significant between-group differences were observed at baseline. At 4 weeks following semaglutide injection, all gastric motility indices were significantly reduced (p < 0.05), with further significant decreases at 8 weeks (p < 0.05). Gastrointestinal transit tests demonstrated progressively increased retention of barium markers in the stomach, an elevated gastric transit index, and a decreased barium excretion rate in the semaglutide group compared with the control group (all p < 0.05). CONCLUSION: Oral contrast-enhanced gastric ultrasonography provides a noninvasive, quantitative method for assessing semaglutide-associated delayed gastric emptying and reduced gastric antral motility. These effects intensify with prolonged treatment duration.

doi.org/10.2147/rmhp.s626020Open accessPubMed 43054650Interventions

AgingResearch.News